Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $28.3 million.

  • Zentalis Pharmaceuticals' Cash from Investing Activities fell 4129.51% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.5 million, marking a year-over-year increase of 2860.46%. This contributed to the annual value of $176.6 million for FY2024, which is 49714.11% up from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Cash from Investing Activities is $28.3 million, which was down 4129.51% from $30.4 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Cash from Investing Activities high stood at $72.9 million for Q2 2023, and its period low was -$142.1 million during Q2 2022.
  • Its 4-year average for Cash from Investing Activities is $7.8 million, with a median of $30.4 million in 2025.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 68672.69% in 2023, then soared by 17675.46% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Cash from Investing Activities stood at -$11.9 million in 2022, then tumbled by 253.62% to -$42.1 million in 2023, then soared by 176.75% to $32.3 million in 2024, then dropped by 12.27% to $28.3 million in 2025.
  • Its Cash from Investing Activities stands at $28.3 million for Q3 2025, versus $30.4 million for Q2 2025 and $40.5 million for Q1 2025.